top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
17 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
17 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


FDA Investigates Cancer Risk With Zolgensma After Vector DNA Found Next to a Tumor Gene
The FDA confirmed that Zolgensma's AAV vector inserted next to the GLI1 cancer gene in two children who developed tumors. Here's what was found and what it means for SMA families and AAV gene therapy.
Nov 7


FDA Approves Voceryq, the First Plasmid DNA Immunotherapy, for Recurrent Respiratory Papillomatosis
The FDA approved Inovio's Voceryq, its first plasmid DNA immunotherapy, for adults with recurrent respiratory papillomatosis. Here's how it works and what the trial showed.
Nov 1


FDA Proposes One Approval for Many Mutations in Personalized Gene Editing
A new FDA draft guidance would let one license cover a personalized gene editor and its patient-specific versions. New mutations could be added with lab data instead of new clinical trials, a path built for cases like KJ Muldoon's.
Oct 29


Beacon's Gene Therapy for X-Linked Retinitis Pigmentosa Succeeds in a Pivotal Trial
Laru-zova met its primary goal in the pivotal VISTA trial: 31% of high-dose patients gained three or more lines of dim-light vision, versus none in the control group. It is the first XLRP gene therapy to win a late-stage trial.
Oct 4


Four Years In, uniQure's Huntington's Gene Therapy Still Slows Decline as It Heads to the FDA
Four-year data for AMT-130 show high-dose patients losing everyday function 61% more slowly than matched untreated patients, but a key composite score weakened. Here's what the results mean as the FDA reviews uniQure's application.
Oct 3


FDA Approves Fayuvi, the First Treatment for Sanfilippo Syndrome Type A
The FDA approved Ultragenyx's Fayuvi (UX111), an AAV9 gene therapy and the first treatment of any kind for Sanfilippo syndrome type A, often called childhood Alzheimer's. Here's how it works and what the data showed.
Sep 16


FDA Grants Priority Review to What Could Be the World's First In Vivo CRISPR Therapy
The FDA accepted Intellia's application for lonvo-z in hereditary angioedema with priority review, setting a March 10, 2027 decision date. It could be the first CRISPR therapy that edits genes inside the body.
Sep 7


FDA Places New Clinical Hold on Regenxbio's Hunter Syndrome Gene Therapy
The FDA placed a clinical hold on Regenxbio's RGX-121 for Hunter syndrome after MRIs found spinal nodules in 5 of 48 patients, derailing plans to resubmit. Here's the science and the timeline.
Aug 23


One CRISPR Dose, 87% Fewer Attacks: Inside Intellia's Phase 3 Win for Hereditary Angioedema
Intellia's one-time CRISPR therapy lonvo-z cut hereditary angioedema attacks by 87% in the Phase 3 HAELO trial. In its August update, the company set a U.S. launch target of early 2027. Here's how it works.
Aug 5


Prime Medicine Wins Arbitration Against Beam, Clearing the Way for Its AATD Prime Editor
An arbitration tribunal confirmed Prime Medicine's rights to PM647, a prime-editing therapy for alpha-1 antitrypsin deficiency, ending a dispute with Beam Therapeutics. Here's the science and what comes next.
Jul 7


FDA Reverses Course on uniQure's Huntington's Gene Therapy
In June 2026 the FDA agreed that three-year data for uniQure's AMT-130 could support accelerated approval for Huntington's disease, reversing its late-2025 stance. Here's the science and the regulatory drama.
Jun 16


FDA Draft Guidance Lets Gene-Editing Developers Build on What's Already Known
A June 2026 FDA draft guidance lets developers of genome-editing therapies reuse prior manufacturing, nonclinical and clinical knowledge. Here's why the platform approach could speed rare-disease cures.
Jun 2


A Gene Therapy for Dravet Syndrome Cuts Seizures and Supports Development
At ASGCT 2026, Encoded Therapeutics shared one-year data for ETX101, an AAV9 gene regulation therapy for Dravet syndrome that cut seizures by about 76% at the top dose. A pivotal study is now underway.
May 12


Grace Science's GS-100 Earns RMAT Designation for NGLY1 Deficiency
Grace Science's GS-100, an AAV9 gene therapy for NGLY1 deficiency, earned FDA RMAT designation after treated children showed gains in motor and cognitive skills. Here's how it works and why it matters.
Apr 13


Prime Medicine Seeks FDA Approval for the First Prime-Editing Therapy
Prime Medicine plans to seek FDA approval for a prime-editing treatment for chronic granulomatous disease based on two patients. Here's what prime editing is and why this filing is a test case.
Mar 27


FDA Approves Kresladi, the First Gene Therapy for Severe LAD-I
The FDA has approved Kresladi, the first gene therapy for severe leukocyte adhesion deficiency type I (LAD-I). By adding a working ITGB2 gene to a child's own stem cells, it gives white blood cells back the grip they need to leave the bloodstream and fight infection, with no donor needed.
Mar 25
bottom of page


